Loading patent…
OwnerKhallar Abdumuslimovich Alikhanov, Leonid Yazonovich Kacharava +2inventors
InventorsKhallar Abdumuslimovich Alikhanov, Leonid Yazonovich Kacharava, Bagoadi Asumusumovich Alikhanov, Peter Georgievich Prokopenko
Estimating the term…
The invention relates to medicine. The inventive agent which exhibits immunoregulatory properties and accelerated clinical performance at a recrudescence stage and is mainly used for treating autoimmune diseases comprises trophoblastic β-1-glycoprotein and immunoglobulin (Ig) which is embodied in the form of a multivalent ligand G (Ig-G) or A (Ig-A) or M (Ig-M) immunoglobulin. According to the second invention, an agent for treating autoimmune diseases comprises β-1-glycoprotein and immunoglobulin (Ig-G), wherein the multivalent ligand G or A (Ig-A) is used in the form of an immunoglobulin and the β-1-glycoprotein and immunoglobulin (Ig-G) are taken in equal portions on in portions whose ratio is equal to 1:19, respectively. For treating autoimmune diseases, the agent containing β-1-glycoprotein and immunoglobulin (Ig) is parenterally administratable.
An agent with the property to induce the suppressor activity and cytokine secretion of mononuclear cells that contains trophoblastic β-1-glycoprotein (TBG), distinctive in that it also contains immunoglobulin (Ig).
An agent per item 1, distinctive in that immunoglobulin class G (Ig-G), or class A (Ig-A), or class M (Ig-M) is used as immunoglobulin.
An agent per item 1, distinctive in that TBG and Ig are used in equal ratio.
An agent per item 1, distinctive in that TBG and Ig are used in the ratio of 1:19, respectively.
The use of an agent with the property to induce the suppressor activity and cytokine secretion of mononuclear cells that contains TBG and immunoglobulin (Ig) for treatment of autoimmune diseases.
The use of the agent per item 5, distinctive in that class G (Ig-G), or class A (Ig-A), or class M (Ig-M) immunoglobulin is used as immunoglobulin.
The use of an agent per item 5, distinctive in that it is administered parenterally.
The use of the agent per item 6, distinctive in that TBG and Ig are used in equal ratio.
The use of the agent per item 6, distinctive in that TBG and Ig are used in the ratio of 1:19, respectively.
Dependencies are inferred from the claim text.